Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Update

Oruka Therapeutics, Inc. (NASDAQ:ORKA) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 7,626,531 shares, a growth of 30.8% from the December 15th total of 5,830,860 shares. Currently, 20.9% of the company’s stock are sold short. Based on an average daily volume of 904,485 shares, the days-to-cover ratio is presently 8.4 days. Based on an average daily volume of 904,485 shares, the days-to-cover ratio is presently 8.4 days. Currently, 20.9% of the company’s stock are sold short.

Oruka Therapeutics Stock Up 2.8%

NASDAQ ORKA traded up $0.90 during midday trading on Friday, hitting $33.40. The company had a trading volume of 715,063 shares, compared to its average volume of 667,615. The firm has a fifty day simple moving average of $29.60 and a two-hundred day simple moving average of $22.11. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $33.85. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -17.58 and a beta of -0.39.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.01. As a group, equities analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $31.81, for a total transaction of $222,670.00. Following the completion of the sale, the insider owned 1,518 shares of the company’s stock, valued at $48,287.58. This trade represents a 82.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 24.69% of the stock is currently owned by insiders.

Institutional Trading of Oruka Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ORKA. Financial Enhancement Group LLC bought a new position in shares of Oruka Therapeutics during the 3rd quarter worth about $631,000. B Group Inc. increased its stake in Oruka Therapeutics by 28.8% in the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock valued at $841,000 after acquiring an additional 16,785 shares during the period. Geode Capital Management LLC raised its position in Oruka Therapeutics by 100.6% in the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after purchasing an additional 354,821 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in Oruka Therapeutics by 10.7% during the second quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock worth $6,765,000 after purchasing an additional 58,117 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Oruka Therapeutics by 40.6% during the second quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock worth $11,355,000 after purchasing an additional 292,421 shares during the period. 56.44% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. UBS Group started coverage on shares of Oruka Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective for the company. Barclays started coverage on shares of Oruka Therapeutics in a report on Monday, October 13th. They issued an “overweight” rating and a $48.00 target price on the stock. HC Wainwright decreased their price target on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, October 27th. Finally, Piper Sandler assumed coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $50.67.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.